Net Sales at Rs 949.42 crore in December 2024 up 17.9% from Rs. 805.26 crore in December 2023. Quarterly Net Profit at Rs.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Shares of GlaxoSmithKline Pharmaceuticals hit the 20 percent upper circuit at ₹2,421.30 per share on the BSE on Monday, February 17, following an impressive financial performance in the quarter ended ...

GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the BSE.The ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

India's GlaxoSmithKline Pharma reports higher profit on strong demand for respiratory drugs India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday ...

At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...

Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...

Feb 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...